Related Experiment Video
Updated: Mar 30, 2026

Working with Human Tissues for Translational Cancer Research
Published on: November 26, 2015
[Regulation (EU) No 536/2014 on Clinical Trials and Vulnerable Groups]
1Unidad de Farmacia Clínica y Farmacoterapia. Departamento de Farmacia y Tecnología Farmacéutica. Facultad de Farmacia. Universidad de Barcelona. Avda. Juan XXIII s/n. 08028 Barcelona. emarino@ub.edu.
Abstract:
A complete review of the normative established for clinical trials in vulnerable patient is performed. To do that, the basis is the last European norm, that is, the Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA relevance). It is checked all related to vulnerable patients from the previous European norm. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 and the corresponding transpositions into Spanish law by Royal Decree 223/2004 , of February 6, 2004 , whereby clinical drug trials and Law 29/2006 of 26 July, on guarantees and regulates use rational use of medicines and health products.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
Bioavailability Study Design: Healthy Subjects Versus Patients

